INCYTE CORP (INCY) Insider Transactions
Over the last 12 months, 22 INCYTE CORP (INCY) insiders filed 195 SEC Form 4 transactions — $0 in open-market purchases ( 0 distinct buyers) and $43.8M in open-market sales. 2% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $0Open-market buys (1y)
- $43.8MOpen-market sells (1y)
- 22Distinct insiders
- 195Transactions filed
- 2%Under Rule 10b5-1 plan
- 2026-07-23Latest filing
Recent Form 4 Filings Most recent 50 of 195 (1-year window)
Each row is a single Form 4 filing event for INCY, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-07-23 | Heeson Lee | EVP, Head of Incyte Intl | Grant | A | $0 | 15,423 | $0.0 |
| 2026-07-23 | Heeson Lee | EVP, Head of Incyte Intl | Grant | A | $0 | 13,498 | $0.0 |
| 2026-07-23 | Morrissey Michael James | EVP, Head of Tech. Operations | Grant | A | $0 | 6,426 | $0.0 |
| 2026-07-23 | Morrissey Michael James | EVP, Head of Tech. Operations | Grant | A | $0 | 8,999 | $0.0 |
| 2026-07-16 | Tray Thomas | Principal Accounting Officer | Grant | A | $0 | 2,834 | $0.0 |
| 2026-07-16 | Tray Thomas | Principal Accounting Officer | Grant | A | $0 | 4,079 | $0.0 |
| 2026-07-16 | Stein Steven H | CMO & Head of Late-Stage Dev. | Grant | A | $0 | 9,798 | $0.0 |
| 2026-07-16 | Stein Steven H | CMO & Head of Late-Stage Dev. | Grant | A | $0 | 24,496 | $0.0 |
| 2026-07-16 | Stein Steven H | CMO & Head of Late-Stage Dev. | Grant | A | $0 | 42,298 | $0.0 |
| 2026-07-16 | Mayes Patrick A | EVP & Chief Scientific Officer | Grant | A | $0 | 5,916 | $0.0 |
| 2026-07-16 | Mayes Patrick A | EVP & Chief Scientific Officer | Grant | A | $0 | 14,790 | $0.0 |
| 2026-07-16 | Mayes Patrick A | EVP & Chief Scientific Officer | Grant | A | $0 | 25,538 | $0.0 |
| 2026-07-16 | CAGNONI PABLO J | President, Global Head of R&D | Grant | A | $0 | 13,403 | $0.0 |
| 2026-07-16 | CAGNONI PABLO J | President, Global Head of R&D | Grant | A | $0 | 33,508 | $0.0 |
| 2026-07-16 | CAGNONI PABLO J | President, Global Head of R&D | Grant | A | $0 | 57,861 | $0.0 |
| 2026-07-16 | Issa Mohamed Khairie | EVP, Head of U.S. Commercial | Grant | A | $0 | 7,857 | $0.0 |
| 2026-07-16 | Issa Mohamed Khairie | EVP, Head of U.S. Commercial | Grant | A | $0 | 19,643 | $0.0 |
| 2026-07-16 | Issa Mohamed Khairie | EVP, Head of U.S. Commercial | Grant | A | $0 | 33,918 | $0.0 |
| 2026-07-16 | Basi Ramitpal K | EVP, Human Resources | Grant | A | $0 | 4,991 | $0.0 |
| 2026-07-16 | Basi Ramitpal K | EVP, Human Resources | Grant | A | $0 | 12,479 | $0.0 |
| 2026-07-16 | Basi Ramitpal K | EVP, Human Resources | Grant | A | $0 | 21,548 | $0.0 |
| 2026-07-16 | Gardner David H | EVP, Chief Strategy Officer | Grant | A | $0 | 7,395 | $0.0 |
| 2026-07-16 | Gardner David H | EVP, Chief Strategy Officer | Grant | A | $0 | 18,487 | $0.0 |
| 2026-07-16 | Gardner David H | EVP, Chief Strategy Officer | Grant | A | $0 | 31,923 | $0.0 |
| 2026-07-16 | Hoffman Richard A. | EVP & General Counsel | Grant | A | $0 | 7,395 | $0.0 |
| 2026-07-16 | Hoffman Richard A. | EVP & General Counsel | Grant | A | $0 | 18,487 | $0.0 |
| 2026-07-16 | Hoffman Richard A. | EVP & General Counsel | Grant | A | $0 | 31,923 | $0.0 |
| 2026-07-16 | Meury William | Chief Executive Officer | Grant | A | $0 | 26,807 | $0.0 |
| 2026-07-16 | Meury William | Chief Executive Officer | Grant | A | $0 | 80,421 | $0.0 |
| 2026-07-16 | Meury William | Chief Executive Officer | Grant | A | $0 | 77,148 | $0.0 |
| 2026-07-16 | Stein Steven H | CMO & Head of Late-Stage Dev. | Sell | S | $215.3K | 1,877 | $114.7 |
| 2026-07-16 | Issa Mohamed Khairie | EVP, Head of U.S. Commercial | Sell | S | $125.7K | 1,093 | $115.0 |
| 2026-07-15 | CAGNONI PABLO J | President, Global Head of R&D | Other | F | $569.7K | 4,950 | $115.1 |
| 2026-07-15 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | F | $174.0K | 1,512 | $115.1 |
| 2026-07-15 | Tray Thomas | Principal Accounting Officer | Other | F | $126.4K | 1,098 | $115.1 |
| 2026-07-15 | Stein Steven H | CMO & Head of Late-Stage Dev. | Other | F | $355.4K | 3,088 | $115.1 |
| 2026-07-15 | Issa Mohamed Khairie | EVP, Head of U.S. Commercial | Other | F | $126.5K | 1,099 | $115.1 |
| 2026-07-15 | Stein Steven H | CMO & Head of Late-Stage Dev. | Sell | S | $3.2M | 28,237 | $113.0 |
| 2026-07-14 | CAGNONI PABLO J | President, Global Head of R&D | Other | F | $2.1M | 17,969 | $114.9 |
| 2026-07-14 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | F | $50.2K | 437 | $114.9 |
| 2026-07-14 | Tray Thomas | Principal Accounting Officer | Other | F | $79.5K | 692 | $114.9 |
| 2026-07-14 | Stein Steven H | CMO & Head of Late-Stage Dev. | Other | F | $2.5M | 21,830 | $114.9 |
| 2026-07-02 | Mayes Patrick A | EVP & Chief Scientific Officer | Other | F | $40.9K | 350 | $116.9 |
| 2026-07-02 | Tray Thomas | Principal Accounting Officer | Other | F | $55.7K | 477 | $116.9 |
| 2026-07-02 | Meury William | Chief Executive Officer | Other | F | $558.5K | 4,779 | $116.9 |
| 2026-07-02 | Stein Steven H | CMO & Head of Late-Stage Dev. | Other | F | $254.4K | 2,177 | $116.9 |
| 2026-06-30 | Clancy Paul J | — | Grant 10b5-1 | A | $28.6K | 252 | $113.4 |
| 2026-06-30 | BAKER BROS. ADVISORS LP | — | Grant | A | $0 | 400 | $0.0 |
| 2026-06-30 | BAKER BROS. ADVISORS LP | — | Grant | A | $0 | 400 | $0.0 |
| 2026-06-30 | HARRIGAN EDMUND | — | Grant 10b5-1 | A | $28.9K | 255 | $113.4 |
Showing the most recent 50 of 195 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Methodology & FAQ
How We Track INCY Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for INCYTE CORP?
Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of INCYTE CORP (INCY) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of INCYTE CORP (INCY) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.